Embecta Corp.: stock overview

EMBCNASDAQHealthcare · Surgical & Medical Instruments & Apparatus

Price

$6.46

November 13, 2026Market cap $378M

DCF calculator

What Ploutos Investor adds for Embecta

Part of Ploutos Investor, €9.99 a month

See the plans

The full history: 6 fiscal years, from FY2020
The estimated fair value, with its range and its certainty
The full analysis, 18 a month
More questions to the chat on its filings
Excel with every year
An email when it reports, changes its dividend or an officer buys

Notes on these figures

The share price has risen 46% since Aug 7, 2026, when the 10-Q these figures come from was filed ($4.42 then, $6.46 on Nov 13, 2026). The figures date from before that move.10-Q
The company lowered its dividend in the past year. The trailing yield still counts the higher payments before the cut.
The latest annual figures the company filed are for 2025, more than a year ago. Newer ones may be late.

In short

Embecta had revenue of $1.0B over the last 12 months and net income of $88M, a net margin of 8.6%. Revenue fell by 0.1% a year on average over the last 5 years. At $6.46 the shares trade at a P/E of 4.3, against a median of 9.6 over the last 4 fiscal years. It has net debt of $1.3B. It pays a dividend yielding 4.95%.

From its SEC filings (latest fiscal year to September 30, 2025) and the price of November 13, 2026.

Its SEC filings

Market cap: $378M; 58.51M shares
P/E: 4.3; Today4.3
Median9.6
Revenue, 12 months: $1.0B; -0.1% a year over 5 years
Net margin: 8.6%; FY2025: 8.8%, above 67% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

FY2023–FY2025 fiscal years

-1.8% a year over 2 years

FY2025Sep 30, 202510-K
Revenue$1.1B
FY2024Sep 30, 202410-K
Revenue$1.1B
FY2023Sep 30, 202310-K
Revenue$1.1B

Year	Revenue	Net income	EPS	Free cash flow	Dividend per share	Price
FY2025Sep 30, 202510-K	$1.1B	$95M	$1.62	$182M	$0.60	$14.11
FY2024Sep 30, 202410-K	$1.1B	$78M	$1.34	$20M	$0.60	$14.10
FY2023Sep 30, 202310-K	$1.1B	$70M	$1.22	$41M	~$0.60	$15.05

Fiscal years in figures

EMBC's revenue, profit, cash flow and dividend with each year-end price, from FY2020 to FY2022, 3 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $826M: $378M
Enterprise value: $1.6B
P/E 3-year median: 10.5: 4.3
EV / EBIT: 7.4
EV / Revenue: 1.6
P/B: –
FCF yield 3-year median: 4.8%: 43.6%
Earnings yield 3-year median: 9.5%: 23.2%

Profitability

Gross margin: 59.0%
Operating margin: 21.9%
Net margin 3-year median: 7.0%: 8.6%
ROIC: 20.4%
ROIC, 5-year average: 32.7%
ROE: –

Growth

Revenue, yearly change: -3.8%
EPS, yearly change: +20.9%
FCF, yearly change: +816.6%
Revenue, average a year: -0.1%
EPS, average a year: -26.4%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash: $215M
Total debt: $1.5B
Of which operating leases: $16M
Net debt: $1.3B
Net debt / EBITDA: 4.8x
Interest cover: –
Current ratio: 1.68

Balance sheet of June 30, 2026.

Returns to shareholders

Dividend yield 3-year median: 4.3%: 4.95%
Buybacks: –
Total returned: 4.95%
Shares, yearly change: +0.7%

Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 38).

Gross margin

62.6%

Above 63% of the 161 companies in its industry, and 81% of all.

Operating margin

22.4%

Above 92% of the 186 companies in its industry, and 86% of all.

Net margin

8.8%

Above 67% of the 189 companies in its industry, and 63% of all.

ROA

9.0%

Above 80% of the 190 companies in its industry, and 85% of all.

Revenue growth

-3.8%

Above 15% of the 186 companies in its industry, and 19% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC: Embecta Corp.
CIK: 1872789
Exchange: NASDAQ
Industry (SIC): 3841 · Surgical & Medical Instruments & Apparatus
Fiscal year ends: September 30
Latest annual report: September 30, 2025
Reporting currency: USD
Shares: 58.51M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

LLYEli Lilly and Company+0,00%

Compare with EMBC
JNJJohnson & Johnson+0,00%

Compare with EMBC
ABBVAbbVie+0,00%

Compare with EMBC
UNHUnitedHealth+0,00%

Compare with EMBC
MRKMerck & Company+0,00%

Compare with EMBC
AMGNAmgen+0,00%

Compare with EMBC
TMOThermo Fisher Scientific+0,00%

Compare with EMBC
ABTAbbott Laboratories+0,00%

Compare with EMBC

The Healthcare sector All companies

The full analysis

What do Embecta's filings show?

These are Embecta's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

A fair value range built from the filings
Earnings quality, debt and red flags
Insider and institutional moves
The case for and the case against

Questions about EMBC

Didn't find what you were looking for?

Ask us

What is EMBC's market cap?

Embecta Corp.'s market cap is $378M, at a price of $6.46 on November 13, 2026 and 58.51M shares.

What is EMBC's P/E?

EMBC's P/E is 4.3, on earnings per share of $1.47 over the last 12 months. The median over the last 4 fiscal years was 9.6.

How much revenue does EMBC have?

Embecta had revenue of $1.0B over the last 12 months. Over the last 5 years it changed by -0.1% a year on average.

Does EMBC pay a dividend?

Yes. Embecta paid $0.32 per share over the last 12 months, a yield of 4.95% at today's price. All the figures are in the Dividend section.

Where do the figures come from?

From Embecta Corp.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.